Biotechnology Assets Sa Stock Current Valuation
| BST Stock | 0.31 0.01 3.13% |
Valuation analysis of Biotechnology Assets helps investors to measure Biotechnology Assets' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Biotechnology Assets' price fluctuation is out of control at this time. Calculation of the real value of Biotechnology Assets is based on 3 months time horizon. Increasing Biotechnology Assets' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biotechnology Assets is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biotechnology Stock. However, Biotechnology Assets' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.31 | Real 0.26 | Hype 0.31 | Naive 0.28 |
The real value of Biotechnology Stock, also known as its intrinsic value, is the underlying worth of Biotechnology Assets Company, which is reflected in its stock price. It is based on Biotechnology Assets' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Biotechnology Assets' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Biotechnology Assets SA helps investors to forecast how Biotechnology stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biotechnology Assets more accurately as focusing exclusively on Biotechnology Assets' fundamentals will not take into account other important factors: Biotechnology Assets SA Company Current Valuation Analysis
Biotechnology Assets' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Biotechnology Assets SA has a Current Valuation of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current valuation for all Spain stocks is 100.0% higher than that of the company.
Biotechnology Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotechnology Assets' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biotechnology Assets could also be used in its relative valuation, which is a method of valuing Biotechnology Assets by comparing valuation metrics of similar companies.Biotechnology Assets is currently under evaluation in current valuation category among its peers.
Biotechnology Fundamentals
| Return On Equity | -0.74 | |||
| Return On Asset | -0.0647 | |||
| Profit Margin | (0.92) % | |||
| Operating Margin | (0.63) % | |||
| Shares Outstanding | 48.35 M | |||
| Shares Owned By Insiders | 51.21 % | |||
| Revenue | 3.28 M | |||
| Gross Profit | 3.01 M | |||
| EBITDA | (1.04 M) | |||
| Book Value Per Share | 0.1 X | |||
| Number Of Employees | 33 | |||
| Beta | 1.51 | |||
| Market Capitalization | 13.64 M | |||
| Annual Yield | 0.53 % |
About Biotechnology Assets Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotechnology Assets SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotechnology Assets using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotechnology Assets SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Biotechnology Stock
Biotechnology Assets financial ratios help investors to determine whether Biotechnology Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Assets security.